Annals of Family Medicine
NOVEMBER 20, 2024
’s (2006) framework. long-term nursing homes, clinics), highlighting their perceived needs. Employing thematic analysis, seven distinct themes emerged, which were then classified across four overarching levels: societal, institutional, organizational, and individual.
FDA Law Blog
MARCH 7, 2024
Clissold — The trio of CDER, CBER, and CDRH released a new draft guidance titled “ Use of Data Monitoring Committees in Clinical Trials ” that revises the 2006 guidance “Establishment and Operation of Clinical Trial Data Monitoring Committees” and, when final, will replace the 2006 guidance.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Physician's Weekly
JUNE 15, 2025
They evaluated 442 participants from the Collaborative Retrospective Study of Retinal Optical Coherence Tomography in Neuromyelitis optica (CROCTINO) cohort for comorbidities which included 515 individuals—369 with AQP4-NMOSD, 54 with MOGAD, and 58 with DN-NMOSD—meeting the 2006 and 2015 diagnostic criteria for NMOSD.
Today's Hospitalist
APRIL 24, 2025
That checklist includes patient demographics and the individual patient’s clinical needs. ” Phyllis Maguire has been Executive Editor of Today’s Hospitalist since 2006. Both the bed assignment countermeasure and the nursing handoff come with time expectations. Based in Bucks County, Pa.,
FDA Law Blog
NOVEMBER 1, 2023
Regulating LDTs: A Long and Winding Road In what might sound to some like protesting too much, the PR invokes FDA’s longstanding assertion that IVDs “manufactured” by laboratories are medical devices and that clinical laboratories that develop tests are acting as manufacturers. FDA’s position is, however, only one side of the story.
FDA Law Blog
DECEMBER 12, 2022
This form lists important risks, including those known or reported to be associated with the use of the LASIK laser devices based on information from clinical trials, scientific literature, and reports from patients who have undergone LASIK. After reviewing the information. please read and discuss the items in this checklist with your doctor.
Today's Hospitalist
JUNE 7, 2025
They presented a rapid clinical update Webinar in May 2025 hosted by the Society of Hospital Medicine. ” All anti-obesity medications, even the earlier generation of these drugs—which include orlistat, phentermine, phentermine/topiramate (Qsymia) and naltrexone/bupropion (Contrave)—cause clinically significant weight loss.
Expert insights. Personalized for you.
130 
Let's personalize your content